Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019
August 22 2019 - 7:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that it
will release its financial results for the second quarter ended
June 30, 2019 after the close of market on Tuesday, September 3,
2019. Company management will host a conference call and webcast to
discuss its financial results and provide a general business update
at 4:30 p.m. Eastern time on the same day.
Conference Call Details
The conference call will be webcast live from the company’s
website and will be available via the following link:
https://edge.media-server.com/mmc/p/tk8ypudk. Please access the
webcast at least 10 minutes before the conference call start
time.
To access the live conference call via phone, please dial
877-282-2581 from the United States and Canada, or +1 470-495-9479
internationally, at least 10 minutes prior to the start of the
call, using the conference ID 2368125.
A replay of the webcast will be available for two weeks
following the conclusion of the live broadcast and will be
accessible on the company’s website at www.CastleBiosciences.com
from the “Investors” page.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a commercial-stage
dermatologic cancer company focused on providing physicians and
their patients with personalized, clinically actionable genomic
information to make more accurate treatment decisions. The Company
currently offers tests for patients with cutaneous melanoma
(DecisionDx®-Melanoma, DecisionDx®-CMSeq; www.SkinMelanoma.com) and
uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and
DecisionDx®-UMSeq; www.MyUvealMelanoma.com), with products in
development for other underserved cancers, the two most advanced of
which are focused on patients with cutaneous squamous cell
carcinoma, and patients who have a difficult-to-diagnose pigmented
lesion. Castle Biosciences is based in Friendswood, Texas
(Houston), and has laboratory operations in Phoenix, Arizona. For
more information, visit www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are the trademarks of Castle
Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190822005175/en/
Frank Stokes, CFO 866-788-9007 IR@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024